Die unkomplizierte Harnwegsinfektion

Hof, Herbert

doi:10.1007/s00129-018-4263-z

Cited by 3 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nitroxoline is recommended for the calculcated therapy of uncomplicated UTIs in adults [24]. However, it also appears to be a promising candidate for the therapy of MDR Enterobacterales, as it is active against practically all strains of E. coli and most other tested enterobacterial uropathogens, although not against Pseudomonas aeruginosa [25,26]. Nitroxoline retains its antibacterial activity even against challenging bacteria such as 3rd generation cephalosporin-and/or quinolone-resistant enterobacteria [25,27,42].…”

Section: Co-localisation Of Transferable Resistance To Cotrimoxazole Esbl and Quinolonesmentioning

confidence: 99%

“…Since nitroxoline is active against a broad spectrum of different Gram-negative and Gram-positive bacteria as well as against yeasts isolated from urine samples from patients [24][25][26][27][28][29], it can also be considered as another possible treatment for UTIs. In the new German guidelines for uncomplicated UTIs, nitroxoline is recommended as one of the drugs of primary choice for calculated therapy of UTIs in adults [24,30].…”

Section: Introductionmentioning

confidence: 99%

“…This drug is even active against bacteria in biofilms [27,31]. Other causative agents of UTIs, such as Pseudomonas aeruginosa and Enterococcus faecalis are, however, generally resistant [25,26]. Oral application results in high concentrations of nitroxoline and its active metabolite nitroxoline sulfate in urine, which is a prerequisite for successful therapy of uropathogens [32].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Compared with Cotrimoxazole Nitroxoline Seems to Be a Better Option for the Treatment and Prophylaxis of Urinary Tract Infections Caused by Multidrug-Resistant Uropathogens: An In Vitro Study

et al. 2021

Self Cite

View full text Add to dashboard Cite

The resistance of uropathogens to various antibiotics is increasing, but nitroxoline remains active in vitro against some relevant multidrug resistant uropathogenic bacteria. E. coli strains, which are among the most common uropathogens, are unanimously susceptible. Thus, nitroxoline is an option for the therapy of urinary tract infections caused by multiresistant bacteria. Since nitroxoline is active against bacteria in biofilms, it will also be effective in patients with indwelling catheters or foreign bodies in the urinary tract. Cotrimoxazole, on the other hand, which, in principle, can also act on bacteria in biofilms, is frequently inactive against multiresistant uropathogens. Based on phenotypic resistance data from a large number of urine isolates, structural characterisation of an MDR plasmid of a recent ST131 uropathogenic E. coli isolate, and publicly available genomic data of resistant enterobacteria, we show that nitroxoline could be used instead of cotrimoxazole for intervention against MDR uropathogens. Particularly in uropathogenic E. coli, but also in other enterobacterial uropathogens, the frequent parallel resistance to different antibiotics due to the accumulation of multiple antibiotic resistance determinants on mobile genetic elements argues for greater consideration of nitroxoline in the treatment of uncomplicated urinary tract infections.

show abstract